Vascular Biogenics Ltd (NASDAQ:VBLT) Receives Consensus Rating of “Buy” from Brokerages
Posted by Scott Moore on Jun 17th, 2016 // No Comments
Vascular Biogenics logoShares of Vascular Biogenics Ltd (NASDAQ:VBLT) have earned a consensus rating of “Buy” from the six brokerages that are presently covering the company. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $14.67.
VBLT has been the topic of a number of recent research reports. JMP Securities dropped their price objective on shares of Vascular Biogenics from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 9th. Piper Jaffray reaffirmed a “buy” rating and issued a $14.00 price target on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Chardan Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Roth Capital reissued a “buy” rating and set a $22.00 price objective on shares of Vascular Biogenics in a report on Thursday, June 9th.
Shares of Vascular Biogenics (NASDAQ:VBLT) traded down 2.83% on Friday, reaching $4.46. The company’s stock had a trading volume of 1,195,441 shares. The firm’s 50 day moving average is $3.81 and its 200-day moving average is $3.79. The stock’s market cap is $100.24 million. Vascular Biogenics has a 52-week low of $2.76 and a 52-week high of $12.25.
Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). On average, equities research analysts forecast that Vascular Biogenics will post ($0.84) EPS for the current year.
The phase 2 news was great! That got the attention of the stock pimps that saw VBLT trade 30 million shares On Momday. The day traders delight de jour ! I'm not hating that, just observing and parking my $ in VBLT.
Sit back and relax folks, money to be made here. I've been Long 1,700 sh.and holding.
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis DataGlobeNewswire